A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.
Doreen BarrettSanela BilicYung ChyungShaun M CoteRyan IarrobinoKatherine KacenaAshish KalraKimberly LongGeorge NomikosAmy PlaceJames Gordon StillLeela VrishabhendraPublished in: Advances in therapy (2021)
These results support continued investigation of apitegromab for the treatment of patients with milder forms (type 2 and 3) of spinal muscular atrophy.
Keyphrases